|
 |
Albert Deisseroth's References
with links to PubMed
Fujii T, Austin D, Guo D, Srimatkandada S, Wang T, Kubushiro K, Masumoto
N, Tsukazaki K, Nozawa S, Deisseroth AB.
Peptides inhibitory for the transcriptional regulatory function of human papillomavirus
E2.
Clin Cancer Res. 2003 Nov 1;9(14):5423-8.
Zhang L, Tang Y, Akbulut H, Zelterman D, Linton PJ, Deisseroth AB.
An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand
fusion protein to dendritic cells.
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15101-6.
Akbulut H, Zhang L, Tang Y, Deisseroth A.
Cytotoxic effect of replication-competent adenoviral vectors carrying
L-plastin promoter regulated E1A and cytosine deaminase genes in cancers
of the breast, ovary and colon.
Cancer Gene Therapy, 10:388-395, 2003.
Akbulut, H, and Deisseroth, A.
Prevention of Cervical Cancer.
In Progress
in Oncology 2002. Eds. VT DeVita,Jr, S. Hellman, and SA Rosenberg. Jones
and Bartlett Publishers, Boston, MA pp. 251-269, 2002. Zhang
L, Akbulut H, Tang Y, Peng X, Pizzorno G, Sapi E, Manegold S, Deisseroth
A.
Adenoviral vectors with E1A Tumor specific promoters are selectively cytolytic
for breast cancer and on melanoma.
Molecular
Therapy, 6:386-393, 2002.
Peng XY, Won JH, Rutherford T, Fujii T, Zelterman D, Pizzorno G, Sapi E,
Leavitt J, Kacinski B, Crystal R, Schwartz P, Deisseroth A.
The use of the L-plastin promoter for adenoviral mediated tumor-specific gene
expression in ovarian and bladder cancer cell lines
Cancer
Research, 61: 4405-4413, 2001.
Leonard KA, Deisseroth AB, Austin DJ.
Combinatorial chemistry in cancer drug development
The
Cancer Journal, Scientific American, 7: 79-83, 2001.
Lerma E, Wang, T, Fujii, T, Chang, V., Austin D, and Deisseroth, A.
Limitations
of inhibitors of Abl tyrosine specific kinase.
In CML: Biol. and Treatment.
Ed. A. Carella,et al. Martin Dunitz, Publ. London, pp. 493-499, 2001. Fujii
T, Brandsma JL, Peng X, Srimatkandada S, Li L, Canaan A, Deisseroth AB.
High and low levels of cottontail rabbit papillomavirus E2 protein generate
opposite effects on gene expression
J
Biol Chem, 276: 867-874, 2001.
Deisseroth A, and Kluger, H.
New directions in breast cancer treatment
using stem cells, vaccines and genetic therapy.
In Seminars in Breast Dis, Eds. G. Hortobagyi and K. Antman, vol. 3, #3, pp.
1-6, 2000.
Hsieh FT, Mechanic SA, Snyder E, and Deisseroth A.
Blood types, tissue
typing and transfusion of blood products.
Chapter 257, pp 338-345, Kelly’s
Textbook of Int. Medicine, 4th edition, Ed. H.D. Humes, Lippincott, Phil,PA.,
2000. Hortobagyi
GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt
S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE,
Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE.
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk
primary breast carcinoma.
JNCI
92: 225-234, 2000.
Srimdkandada, S., Fujii, T., Wang, T., Fu, S.Q., Yin, L.H., Guo, X.Y.D.,
Nanakorn, T., Peng, X.Y., Wang, W.L., Zhang,L, Canaan, A., Anderson,
M., Dizon, D., Lin, D., Cooperberg, M., Loewe, R., Savinov, S., Liu, F.,
Won,
J.G., Austin, D., and Deisseroth, A.
Molecular therapy of solid tumors and
hematopoietic neoplasms.
In Gene Therapy of Cancer: Methods and Protocols.
Eds. W. Walther, and U. Stein, Humana Press, Totowa, New Jersey, pp.
609-616, 2000.
Mota, A, and Deisseroth A.
Chemotherapy and Biological Therapy of Melanoma,
in Cutaneous Melanoma, Ed. S. Ariyan, Clinics in Plastic Surgery,
W.B. Saunders
Co.27: 463-474, 2000. Deisseroth, A., Psyrri A, and Austin D. Molecular therapy of cancer, in
Principles and Practice of Oncology, 6th Edition, eds. DeVita, Jr., V,
Rosenberg S, and Hellman,S, Lippincott Williams and Wilkins, Philadelphia,
PA, 3180-3187, 2000. Koenig
JM, Baron S, Luo D, Benson NA, Deisseroth AB.
L-Selectin expression enhances clonogenesis of CD34+ cord blood progenitors
Pediatric
Research 45: 867-870, 1999.
Bachier CR, Giles RE, Ellerson D, Hanania EG, Garcia-Sanchez F, Andreeff
M, Cabanillas F, Champlin R, Choudhury R, Berenson R, Heimfeld S, Deisseroth
AB.
Hematopoietic Retroviral Gene Marking in Patients with Follicular Non Hodgkin's
Lymphoma
Leukemia
and Lymphoma, 32: 279-288, 1999.
Guo XY, Balague C, Wang T, Randhawa G, Yuan Z, Bachier C, Greenberger
J, Arlinghaus R, Kufe D, Deisseroth AB.
The presence of the Rb c-box peptide in the cytoplasm inhibits p210bcr-abl transforming
function
Oncogene,
18: 1589- 1595, 1999.
Przepiorka D, Khouri I, Thall P, Mehra R, Lee MS, Ippoliti C, Giralt S,
Gajewski J, van Besien K, Andersson B, Korbling M, Deisseroth AB, Champlin
R.
Thiotepa, Busulfan and Cyclophosphamide as a preparative regimen for allogeneic
translantation for advanced CML
Bone
Marrow Trans 23:977-981, 1999.
Lane CM, Guo XY, Macaluso LH, Yung KC, Deisseroth AB.
Presence of p21bcrabl is associated with decreased expression of beta-chemokine
C10 in a p210bcrabl positive myeloid cell line
Molecular
Medicine 5: 55-61, l999.
Chung I, Schwartz PE, Crystal RG, Pizzorno G, Leavitt J, Deisseroth AB.
Use of L-plastin promoter to develop an adenoviral system that confers transgene
expression in ovarian cancer cells but not in normal mesothelial cells.
Cancer
Gene Therapy, 6:99-106, l999. Garcia-Sanchez F, Pizzorno G,
Fu SQ, Nanakorn T, Krause DS, Liang J, Adams E, Leffert JJ, Yin LH, Cooperberg
MR, Hanania E, Wang WL, Won JH, Peng XY, Cote R, Brown R, Burtness B,
Giles R, Crystal R, Deisseroth AB.
Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce
breast cancer cells 1 million-fold when they contaminate hematopoietic cells:
a potential purging method for autologous transplantation
Blood,
92:672-682, l998.
Deng G, Lane C, Kornblau S, Goodacre A, Snell V, Andreeff M, Deisseroth
AB.
Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets
of acute myeloid leukemia.
Molecular
Medicine, 4: 158-164, l998. Wang MW, Consoli U, Lane CM, Durett
A, Lauppe MJ, Champlin R, Andreeff M, Deisseroth AB.
Rescue from Apoptosis in Early (CD34 Selected) versus Late (CD34 Unselected)
Human Hematopoietic Cells by VLA-4 and VCAM-1 Dependent Adhesion to Bone Marrow
Stromal Cells
Cell
Growth and Differentiation, 9: 105-112, l998.
Guo XY, Cuillerot JM, Wang T, Wu Y, Arlinghaus R, Claxton D, Bachier
C, Greenberger J, Colombowala I, Deisseroth AB.
Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed
phenotype of p210bcr-abl positive 32D myeloid leukemia cells
Oncogene
17:825-833, l998.
Rahman Z, Kavanagh J, Champlin R, Giles R, Hanania E, Fu S, Zu Z, Mehra
R, Holmes F, Kudelka A, Claxton D, Verschraegen C, Gajewski J, Andreeff
M, Heimfeld S, Berenson R, Ellerson D, Calvert L, Mechetner E, Holzmayer
T, Dayne A, Hamer J, Bachier C, Ostrove J, Deisseroth A, et al.
Chemotherapy immediately following autologous stem-cell transplantation in patients
with advanced breast cancer
Clin
Cancer Res. 4(11):2717-21, 1998.
Fu S, Deisseroth AB.
Use of the cosmid adenoviral vector cloning system for the in vitro construction
of recombinant adenoviral vectors.
Hum Gene Ther. 1997 Jul 20;8(11):1321-30
Hanania EG, and Deisseroth AB
Simultaneous genetic chemoprotection of normal cells and genetic chemosensitization
of breast cancer cells in a mouse cancer gene therapy model
Clinical
Cancer Res. 3:281-286, l997. Henderson YC, Chou M, Deisseroth
AB.
IRF-1 induces expression of the interferon stimulated genes in K562 cells
Brit.
J. Haematology, 96: 556-575, l997.
Hanania EG, Giles RE, Kavanagh J, Fu SQ, Ellerson D, Zu Z, Wang T, Su
Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C,
Thall P, Cheng S, Hester J, Ostrove JM, Bird RE, Chang A, Korbling M,
Seong D, Cote R, Holzmayer T, Deisseroth AB, et al.
Results of MDR-1 vector modification trial indicate that CFUGM do not contribute
to post transplant modification trial indicate that granulocyte/macrophage
colony-forming unit cells do not contribute to post transplant hematopoietic
recovery following intensive systemic therapy.
Proc.
Natl. Acad. Sci. USA, 93: 15346-15351, 1996.
Deisseroth AB, Holmes F, Hortobagyi G, Champlin R.
Use of safety-modified retroviruses to introduce chemotherapy resistance sequences
into normal hematopoietic cells for chemoprotection during the therapy of breast
cancer: a pilot trial.
Hum Gene Ther. 1996 Feb 10;7(3):401-16.
Talpaz M, Kantarjian H, Liang J, Calvert L, Hamer J, Tibbits P, Durett
A, Claxton D, Giralt S, Khouri I, et al.
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found
after autologous transplantation for chronic myelogenous leukemia depends on
percentage of diploid cells induced by conventional-dose chemotherapy before
collection of autologous cells.
Blood. 1995 Jun 1;85(11):3257-63.
Kantarjian HM, Talpaz M, Hester J, Feldman E, Korbling M, Liang J,
Rios MB, Smith TL, Calvert L, Deisseroth AB.
Collection of peripheral blood diploid cells from chronic myelogenous
leukemia patients early in the recovery phase from myelosuppression induced
by intensive dose chemotherapy.
J Clin Oncol 13:553-559, 1995.
Hanania EG, Fu S, Zu Z, Hegewisch-Becker S, Korbling M, Hester J,
Durett A, Andreeff M, Mechetner E, Holzmayer T, et.al.
Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction
of CD34 selected marrow and peripheral blood cells with a retrovirus that contains
the MDR-1 chemotherapy resistance gene.
Gene Ther. 1995 Jun;2(4):285-94.
Hanania EG, Fu S, Roninson I, Zu Z, Deisseroth AB.
Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified
retroviruses containing a human MDR-1 transcription unit.
Gene Therapy 2:279-284, 1995.
Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg
L, Thomas M, Janicek K, Anderson WF, et al. Related Articles, Links
Genetic marking shows that Ph+ cells present in autologous transplants of chronic
myelogenous leukemia (CML) contribute to relapse after autologous bone marrow
in CML.
Blood. 1994 May 15;83(10):3068-76.
|
